(52 days)
Not Found
No
The summary describes a passive implantable device (interbody cage) and its manufacturing process. There is no mention of any software, algorithms, or data processing that would indicate the use of AI/ML. The performance studies are based on mechanical testing and finite element analysis, not algorithmic performance metrics.
Yes
The device is used for intervertebral body fusion procedures to treat degenerative disc disease, which involves addressing a medical condition (DDD) in patients.
No
Explanation: The device is an implantable intervertebral body spacer used for spinal fusion, not for diagnosing conditions.
No
The device description clearly states the device is a physical implant made of Titanium alloy and is additively manufactured. It also mentions dedicated surgical instruments. This indicates a hardware-based medical device, not software-only.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is for "intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) of the lumbar spine." This describes a surgical implant used to treat a condition within the body.
- Device Description: The description details a "range of intervertebral body spacers" made of titanium alloy, designed to be implanted surgically. This is consistent with a medical device used for structural support and fusion.
- Lack of IVD Characteristics: An IVD is a medical device used in vitro (outside the body) to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening. This device does not perform any such function. It is a physical implant.
The information provided describes a surgical implant, not a diagnostic test performed on biological samples.
N/A
Intended Use / Indications for Use
Juliet® Ti PO, OL & TL lumbar interbody devices are indicated for intervertebral body fusion procedures in sketally mature patients with degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade 1 spondylolisthesis at the involved level(s). These spinal implants are to be used with autogenous bone graft and/or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft. Juliet® Ti lumbar interbody devices are to be used with supplemental fixation that has been cleared for use in the lumbosacral spine. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral cage.
Product codes (comma separated list FDA assigned to the subject device)
MAX
Device Description
Spineart Juliet® Ti PO & OL spinal implants consist of a range of intervertebral body spacers with various shapes and designs so as to be implanted via an open posterior or transforaminal approach and to adapt different patient anatomy. The devices have a central cavity that can receive autogenous bone graft intended to promote intervertebral fusion. Juliet® Ti PO & OL spinal implants are all made of Titanium alloy Ti6Al4V ELI conforming to ASTM F136. The subject Juliet® Ti PO & OL spinal implants are additively manufactured and present both solid and porous structures.
The subject implants Juliet® Ti OL Insert/Rotate will extend the previously cleared Juliet® Ti (PO, OL & TL) range of implants (K153621) which presents similar design features and the same manufacturing technology, i.e. additive manufacturing (SLM).
The Juliet® Ti PO & OL spinal implants are delivered sterile (gamma sterilization) and supplied with dedicated surgical instruments (reusable - provided non-sterile).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
lumbar spine at one or two contiguous levels from L2-S1
Indicated Patient Age Range
skeletally mature patients
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
No additional testing has been performed for the subject Spineart Juliet® Ti OL Insert/Rotate spinal implants.
Non-clinical tests conducted on predicate devices: Static and dynamic axial compression (per ASTM F2077), Static and dynamic Shear compression (per ASTM F2077) and subsidence (per ASTM F2267). A Finite Element Analysis has been submitted to support substantial equivalence.
Bacterial endotoxin testing as specified in USP standard is used for pyrogenicity testing to achieve the Endotoxin limit of 20 EU / device.
Conclusion: Based on the design features, technological characteristics, feature comparisons and indications for use, the subject Juliet® Ti OL Insert/Rotate has demonstrated substantial equivalence to the identified predicate devices.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Juliet® Ti (K153621) manufactured by Spineart
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
Image /page/0/Picture/0 description: The image contains two logos. The logo on the left is the Department of Health & Human Services - USA logo. The logo on the right is the FDA U.S. Food & Drug Administration logo. The FDA logo is in blue.
June 28, 2018
Spineart Frank Pennesi Chief Technical Officer 3 Chemin du Pré Fleuri Plan Les Quates. 1228 Ch Geneva
Re: K181203
Trade/Device Name: Juliet® Ti Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: MAX Dated: May 25, 2018 Received: May 29, 2018
Dear Mr. Pennesi:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);
1
and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Image /page/1/Picture/6 description: The image contains the text "Melissa Hall -S". The text is written in a simple, sans-serif font. The text is horizontally oriented and appears to be a name followed by an initial. The background is plain and does not distract from the text.
For Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K181203
Device Name Juliet® Ti
Indications for Use (Describe)
Juliet® Ti PO, OL & TL lumbar interbody devices are indicated for intervertebral body fusion procedures in sketally mature patients with degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade 1 spondylolisthesis at the involved level(s). These spinal implants are to be used with autogenous bone graft and/or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft. Juliet® Ti lumbar interbody devices are to be used with supplemental fixation that has been cleared for use in the lumbosacral spine. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral cage.
Type of Use (Select one or both, as applicable)X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Special 510k Juliet® Ti
Image /page/3/Picture/2 description: The image shows the logo for Spineart. The logo consists of the word "spineart" in a stylized font, with a purple butterfly above the text. The "a" in "spineart" is also purple, and there is a registered trademark symbol next to the "t".
510(k) SUMMARY
| 510k | SPECIAL |
|---|---|
| Basis for submission | Extension of the range of Juliet® Ti devices |
| Submitted by | SPINEART |
| 3 Chemin du Pré Fleuri | |
| 1228 PLAN LES OUATES | |
| GENEVA SWITZERLAND | |
| Contacts | Franck PENNESI Chief Technical Officer |
| Phone: +41 22 570 1200 Fax: +41 22 594 8306 | |
| Mail: fpennesi@spineart.com | |
| Regulatory contact: Dr Isabelle DRUBAIX (Idée Consulting) idrubaix@nordnet.fr | |
| Date Prepared | May 3, 2018 |
| Common Name | Intervertebral body fusion device |
| Trade Name | Juliet® Ti |
| Classification Name | Intervertebral Fusion Device with Bone Graft, Lumbar |
| Class | II |
| Product Code | MAX |
| CFR section | 888.3080 |
| Device panel | ORTHOPEDIC |
| Legally marketed predicate devices | Primary predicate: Juliet® Ti (K153621) manufactured by Spineart |
| Indications for use | Juliet® Ti PO, OL & TL lumbar interbody devices are indicated for intervertebral body fusion procedures in skeletally mature patients with degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). These spinal implants are to be used with autogenous bone graft and/or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft. Juliet® Ti lumbar interbody devices are to be used with supplemental fixation that has been cleared for use in the lumbosacral spine. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral cage. |
4
| Description
of
the
device | Spineart Juliet® Ti PO & OL spinal implants consist of a range of intervertebral body spacers with various shapes and designs so as to be implanted via an open posterior or transforaminal approach and to adapt different patient anatomy. The devices have a central cavity that can receive autogenous bone graft intended to promote intervertebral fusion. Juliet® Ti PO & OL spinal implants are all made of Titanium alloy Ti6Al4V ELI conforming to ASTM F136. The subject Juliet® Ti PO & OL spinal implants are additively manufactured and present both solid and porous structures.
The subject implants Juliet® Ti OL Insert/Rotate will extend the previously cleared Juliet® Ti (PO, OL & TL) range of implants (K153621) which presents similar design features and the same manufacturing technology, i.e. additive manufacturing (SLM).
The Juliet® Ti PO & OL spinal implants are delivered sterile (gamma sterilization) and supplied with dedicated surgical instruments (reusable - provided non-sterile). |
|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Technological
characteristics
compared to
the
predicate devices | The Juliet® Ti OL Insert/Rotate spinal implants are manufactured using the same manufacturing technology, i.e. additive manufacturing (SLM) as predicate device Juliet® Ti (PO, OL & TL). The characterization of the chemical, physical and mechanical properties of the material was performed in accordance with ASTM F3001 and ASTM E8/E8M. The porous structure featured on titanium alloy implants additively manufactured was validated based on the FDA's Guidance for industry on the testing of metallic plasma sprayed coatings on orthopedic implants to support reconsideration of postmarket surveillance requirements.
The Juliet® Ti PO & OL spinal implants present a similar design feature and range of devices as the previously cleared Juliet® Ti devices.
The following non-clinical tests were conducted on predicate devices: Static and dynamic axial compression (per ASTM F2077), Static and dynamic Shear compression (per ASTM F2077) and subsidence (per ASTM F2267). A Finite Element Analysis has been submitted to support substantial equivalence.
Bacterial endotoxin testing as specified in USP standard is used for pyrogenicity testing to achieve the Endotoxin limit of 20 EU / device. |
| Discussion of Testing | No additional testing has been performed for the subject Spineart Juliet® Ti OL Insert/Rotate spinal implants. |
| Conclusion | Based on the design features, technological characteristics, feature comparisons and indications for use, the subject Juliet® Ti OL Insert/Rotate has demonstrated substantial equivalence to the identified predicate devices. |